LUPIN:NSE-Lupin Limited (INR)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSE

Last Closing Price

INR 865.40

Change

-5.10 (-0.59)%

Market Cap

INR 392.24B

Volume

3.52M

Average Target Price

INR 877.67 (+1.42%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide. The company offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, anti-TB, and cephalosporin. It also develops drug delivery systems; and provides biosimilars for various therapies, such as rheumatoid arthritis, oncology, ophthalmology, and osteoporosis. In addition, the company offers over-the-counter products, and contract manufacturing and supply services; and engages in the drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as biotechnology research activities. Lupin Limited has a licensing, development, and commercialization agreement with Boehringer Ingelheim for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with cancers. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Employees : 17,684

Currency: INR

Country : India

Technical Indicators

Beta : 0.35

52 Week High : 956.00

52 Week Low : 504.75

200 Day Moving Average : 772.52

50 Day Moving Average : 904.07

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+3.25 (+0.68%)

 INR1,157.68B 28.61 14.91
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+63.20 (+1.65%)

 INR644.45B 33.40 20.54
DIVISLAB:NSE Divi's Laboratories Limited

-21.00 (-0.96%)

 INR574.34B 45.42 29.58
AUROPHARMA:NSE Aurobindo Pharma Limited

+25.70 (+3.31%)

 INR469.86B 17.76 10.83
CADILAHC:NSE Cadila Healthcare Limited

-2.15 (-0.59%)

 INR368.24B 30.10 16.73
ALKEM:NSE Alkem Laboratories Limited

+92.35 (+3.95%)

 INR290.27B 25.42 18.73
IPCALAB:NSE Ipca Laboratories Limited

-7.50 (-0.46%)

 INR206.60B 34.26 21.98
APLLTD:NSE Alembic Pharmaceuticals Limite..

+16.50 (+1.80%)

 INR175.60B 20.40 15.76
NATCOPHARM:NSE NATCO Pharma Limited

+3.25 (+0.48%)

 INR124.75B 26.00 16.56
AJANTPHARM:NSE Ajanta Pharma Limited

+21.60 (+1.54%)

 INR124.24B 26.27 15.68

ETFs Containing LUPIN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.22% 40% F 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.22% 40% F 76% C
Trailing 12 Months  
Capital Gain 15.23% 33% F 80% B-
Dividend Return 0.67% 53% F 37% F
Total Return 15.89% 35% F 80% B-
Trailing 5 Years  
Capital Gain -54.12% 19% F 30% F
Dividend Return 1.72% 36% F 18% F
Total Return -52.40% 21% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -17.10% 17% F 15% F
Dividend Return 0.53% 53% F 37% F
Total Return -16.56% 17% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 15.93% 95% A 93% A
Risk Adjusted Return -103.95% 2% F 5% F
Market Capitalization 392.24B 93% A 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 49.28 13% F 10% F
Price/Book Ratio 3.00 50% F 20% F
Price / Cash Flow Ratio 26.70 31% F 12% F
EV/EBITDA 18.18 21% F 17% F
Management Effectiveness  
Return on Equity -3.03% 10% F 16% F
Return on Invested Capital -10.41% 17% F 13% F
Return on Assets 3.27% 29% F 46% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.35 77% C+ 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.